lorlatinib

inhibits both anaplastic lymphoma kinase and c-ros oncogene 1 (ROS1) protein

Also Known As:

(10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile; 7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile; Lorbrena; PF-06463922; PF06463922; loratinib

Networked: 279 relevant articles (45 outcomes, 46 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Shaw, Alice T: 18 articles (07/2022 - 07/2015)
2.	Peltz, Gerson: 11 articles (11/2022 - 12/2018)
3.	Thurm, Holger: 11 articles (11/2022 - 12/2018)
4.	Gainor, Justin F: 11 articles (07/2022 - 07/2015)
5.	Solomon, Benjamin J: 10 articles (11/2022 - 12/2017)
6.	Pithavala, Yazdi K: 10 articles (03/2022 - 01/2020)
7.	Bauer, Todd M: 9 articles (11/2022 - 12/2017)
8.	Besse, Benjamin: 9 articles (01/2022 - 12/2017)
9.	Chen, Joseph: 9 articles (01/2022 - 12/2017)
10.	Ou, Sai-Hong Ignatius: 9 articles (01/2022 - 01/2017)

Related Diseases

1.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/2021 - "The CROWN study suggests that lorlatinib is effective in patients newly diagnosed with advanced ALK-positive non-small cell lung cancer. " 01/01/2021 - "Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs." 01/01/2020 - " covered: We discuss the structure, pharmacology and efficacy of lorlatinib and also provide future perspectives in the management of patients with ALK-rearranged non-small cell lung cancer (NSCLC).Expert opinion: Patients invariably develop resistance during treatment with lorlatinib. " 11/01/2022 - "Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study." 01/01/2022 - "Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial."
2.	Lung Neoplasms (Lung Cancer) 02/01/2023 - "An update on lorlatinib: a novel first line treatment for ALK-positive advanced lung cancer." 12/01/2019 - "Lorlatinib: a new treatment option for ROS1-positive lung cancer." 11/01/2021 - "Should lorlatinib be the standard first-line treatment in advanced ALK-rearranged lung cancer? " 04/01/2023 - "Multicenter real-world study of individuals with pretreated advanced ALK+ lung cancers managed on a lorlatinib access program between 2016 and 2020. " 08/01/2022 - "Pivotal clinical trials are discussed along with the current status of lorlatinib as a treatment for ALK-positive lung cancer and future therapeutic challenges. "
3.	Neoplasm Metastasis (Metastasis) 01/01/2018 - "In a Phase I/II trial, the safety and efficacy of lorlatinib were demonstrated in patients with advanced ALK-positive NSCLC, most of whom had central nervous system metastases and had previous ALK-TKI treatment. " 10/01/2023 - "Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis." 01/01/2017 - "The patient's central nervous system (CNS) metastases responded to lorlatinib together with clearance of ALK G1202R mutation by repeat ctDNA assay. " 12/01/2017 - "In this phase 1, dose-escalation study, lorlatinib showed both systemic and intracranial activity in patients with advanced ALK-positive or ROS1-positive NSCLC, most of whom had CNS metastases and had previously had two or more TKI treatments fail. " 01/01/2022 - "Fifteen (65%) patients had irradiated CNS metastases, with a median of 20.2 months between radiation and lorlatinib. "
4.	Neuroblastoma 01/01/2023 - "of a phase 1 first-in-child study showcasing the safety and efficacy of lorlatinib against treatment-refractory or relapsed ALK-driven neuroblastoma.1." 01/01/2023 - "Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma." 01/01/2023 - "Cells with these mutations respond to lorlatinib in pre-clinical studies, providing the rationale for a first-in-child Phase 1 trial (NCT03107988) in patients with ALK-driven neuroblastoma. " 01/01/2016 - "Taken together, these results provide the rationale to move PF-06463922 into clinical trials for treatment of patients with ALK-mutated neuroblastoma. " 11/30/2023 - "Finally, we show that lorlatinib-resistant ALK-F1174L neuroblastoma cells harbor additional RAS-MAPK pathway alterations and can be re-sensitized to lorlatinib when combined with TNO155 in vitro and in vivo. "
5.	Neoplasms (Cancer) 01/01/2021 - "In summary, this study identifies an effect of lorlatinib in modulating tumor-associated neutrophils, and demonstrates the potential of lorlatinib to treat PDAC." 09/01/2020 - "Clinical trials show the robust systemic and intracranial anti-tumor activity of lorlatinib in ALK rearranged advanced NSCLC. " 10/01/2014 - "Accordingly, we proposed that the EC60,in vivo for ALK inhibition corresponding to the tumor stasis could be considered a minimum target efficacious concentration of PF06463922 for cancer patients in a phase I trial. " 11/30/2023 - "In murine ALK-mutant xenografts, tumor growth was likewise reduced or delayed, and survival was prolonged upon combinatorial treatment of TNO155 and lorlatinib. " 01/26/2023 - "Xenograft models showed that the combination of EGFR inhibitor and lorlatinib considerably suppressed tumor regrowth following cessation of these treatments. "

Related Drugs and Biologics

1.	Anaplastic Lymphoma Kinase
2.	Crizotinib
3.	alectinib
4.	Tyrosine Kinase Inhibitors
5.	brigatinib
6.	entrectinib
7.	ceritinib
8.	Phosphotransferases (Kinase)
9.	ensartinib
10.	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Combination Drug Therapy (Combination Chemotherapy)
4.	Radiotherapy
5.	Immunotherapy